Daily Broadcaster

(Albany, US) September 27, 2026- DelveInsight’s “Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of HABP, historical and forecasted epidemiology, and HABP market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Download DelveInsight’s comprehensive report to explore HABP Market Trends and Pipeline Analysis @ https://www.delveinsight.com/sample-request/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market

Key Takeaways from the HABP Market Report

• In September 2026, BioVersys AG announced that its lead clinical asset BV100 received FDA Fast Track Designation for the treatment of ventilator-associated bacterial pneumonia (VABP) and hospital-acquired bacterial pneumonia (HABP) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). BV100 is being evaluated in a global Phase III RIV-TARGET trial and a Phase IIb RIV-CARE trial. The designation provides opportunities for more frequent FDA interactions and rolling review.
• As per DelveInsight’s estimates, the incident cases of bacterial pneumonia were highest in the United States among the 7MM in 2024.
• As per the analysis, HABP is more common as compared to VABP in the United States.
• According to the findings, S.aureus, P.aeruginosa, Klebsiella, E.coli, Acinetobacter species and Enterobacter species are pathogens, which are most likely to cause HABP or VABP.
• The leading Hospital-acquired and Ventilator-associated Bacterial Pneumonia Companies, such as Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aridis Pharmaceuticals, Aerucin, Aridis Pharmaceuticals, Motif Bio, and others
• Promising Hospital-acquired and Ventilator-associated Bacterial Pneumonia Therapies such as Linezolid, OMN6, KBPA-101, XNW4107, HRS-8427, Doripenem, Meropenem, Cefiderocol, Cilastatin and others.

Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Treatment Market Size

HABP Overview

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) represent prevalent infections among hospitalized patients, especially those in intensive care units. These conditions are linked to significant mortality rates, financial burdens, and challenges related to antibacterial resistance. Bacterial pneumonia is often classified according to where it is acquired. Hospital-acquired pneumonia, also known as nosocomial pneumonia, occurs 48 hours or more after admission to the hospital and was not likely developing at the time of admission. Ventilator-associated pneumonia is a subtype of hospital-acquired pneumonia that emerges more than 48 hours after endotracheal intubation.

HABP Epidemiology Segmentation in the 7MM

• Total Incident Cases of Bacterial Pneumonia
• Total Incident Cases of HABP/VABP
• Etiology-specific Cases of HABP/VABP
• Treated Cases of HABP/VABP

Download the report to understand which factors are driving HABP epidemiology trends @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Prevalence

HABP Marketed Drugs

• XACDURO: Innoviva

XACDURO, a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, was approved in May 2023 for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The FDA designated it as a Qualified Infectious Disease Product. In July 2022, Innoviva acquired Entasis Therapeutics, the developer of sulbactam-durlobactam.

• FETROJA (cefiderocol): Shionogi

FETROJA (cefiderocol) is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore. In addition to entering cells by passive diffusion through porin channels, FETROJA binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient for bacteria. These mechanisms allow FETROJA to achieve high concentrations in the periplasmic space where it can bind to penicillin-binding proteins and inhibit cell wall synthesis in the bacterial cells. FETROJA has also demonstrated in vitro activity against certain bacteria that contain very problematic resistant enzymes such as ESBLs, AmpC, serine- and metallo-carbapenemases.

HABP Emerging Therapies

• AR-301: Aridis Pharmaceuticals

AR-301 (tosatoxumab) is a fully human monoclonal IgG1 antibody that targets the alpha-toxin produced by S. aureus, a significant virulence factor in both MRSA and MSSA infections. By neutralizing alpha-toxin, AR-301 prevents the destruction of host cells, thereby preserving immune function. Importantly, its mechanism of action is not impacted by the antibiotic resistance of the S. aureus strain, making it effective against both MRSA and MSSA infections. In ongoing Phase III trials, AR-301 is being investigated as an adjunctive therapy alongside standard antibiotics for ventilator-associated pneumonia (VAP) caused by S. aureus. The results show a notable improvement in the clinical cure rate, with a ≥10% increase observed with the addition of AR-301 to standard treatment regimens. Furthermore, the safety profile of AR-301 appears to be satisfactory.

• BV100: Bioversys

BV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing an active uptake of rifabutin into the Gram-negative bacterial species, Acinetobacter baumannii. The candidate allows to target RNA-polymerase in Gram-negative bacteria for the first time with a human-suitable dose. BV100 is currently in Phase II clinical trial undergoing development for the treatment of infections caused by the Acinetobacter baumannii calcoaceticus complex (ABC), including Carbapenem-Resistant ABC (CRAB), in critical indications such as ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP), and bloodstream infections (BSI). It received Qualified Infectious Diseases Product Designation from the US FDA in May 2019 for its potential use in treating VABP, HABP, and BSI.

Discover the future of HABP Treatments with DelveInsight’s latest market report @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Drivers and Barriers

HABP Companies

Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aridis Pharmaceuticals, Aerucin, Aridis Pharmaceuticals, Motif Bio, and others

HABP Treatment Landscape

The current standard of care for hospital-acquired pneumonia is antibiotic therapy, many times given as a combination of up to three different drugs. However, the recent emergence of virulent, antibiotic-resistant bacteria has severely limited the effectiveness of modern antibiotics, leading to increased morbidity and mortality. Antibodies are crucial elements of the human immune system, primarily designed to combat infections. Their excellent safety profile and substantially longer in vivo half-life compared to antibiotics (lasting up to three weeks versus just hours) make them an appealing class of anti-infective agents. This longer duration of protection and less frequent dosing requirement make antibodies an attractive option for patients. Combining monoclonal antibodies with standard antibiotics as adjunctive treatment utilizes the complementary actions of both types of drugs, resulting in superior outcomes compared to either drug used alone. This approach presents a valuable treatment strategy for hospital-acquired infections and addresses the emerging healthcare challenges posed by antimicrobial resistance.

From HABP Market Size to emerging drugs, find it all in our latest report. Read now! @ Hospital-acquired and Ventilator-associated Bacterial Pneumonia Ongoing Clinical Trials Analysis

Scope of the HABP Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• HABP Companies- Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aridis Pharmaceuticals, Aerucin, Aridis Pharmaceuticals, Motif Bio, and others
• HABP Therapies- Linezolid, OMN6, KBPA-101, XNW4107, HRS-8427, Doripenem, Meropenem, Cefiderocol, Cilastatin and others.
• HABP Therapeutic Assessment: HABP Current marketed and HABP Pneumonia Emerging Therapies
• HABP Market Dynamics: HABP market drivers and HABP Market barriers
• HABP Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• HABP Unmet Needs, KOL’s views, Analyst’s views, HABP Market Access and Reimbursement

Table of Contents

1. Key Insights
2. HABP Market Report Introduction
3. HABP Market Overview at a Glance
4. HABP Epidemiology and Market Forecast Methodology
5. HABP Executive Summary
6. HABP Key Events
7. Disease Background and Overview
8. HABP Treatment and Management
9. HABP Epidemiology and Patient Population
10. HABP Patient Journey
11. HABP Marketed Therapies
12. HABP Emerging Therapies
13. HABP: 7 Major Market Analysis
14. HABP KOL Views
15. HABP SWOT Analysis
16. HABP Unmet Needs
17. HABP Reimbursement Scenario
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market